JAK1-selective kinase inhibitor
in clinical development for cancer
from HTS and SBDD of promiscuous hit
J. Med. Chem., Apr. 28, 2020
AstraZeneca, Waltham, MA
AZD4205
AZD4205 is a JAK1-selective kinase inhibitor which is in clinical development for oncology rather than the inflammatory diseases most JAK1 inhibitors have aimed for. The compound has excellent PK in…